| 
		U.S. to widen COVID antiviral pill distribution
		 Send a link to a friend 
		
		 [April 26, 2022] 
		By Ahmed Aboulenein 
 WASHINGTON (Reuters) - President Joe 
		Biden's administration is aiming to expand access to COVID-19 oral 
		antiviral treatments like Pfizer Inc's Paxlovid by doubling the number 
		of locations at which they are available, the White House said on 
		Tuesday.
 
 Pharmacies participating in the federal pharmacy program for 
		distributing antiviral treatments will be able to order the free 
		treatments directly from the U.S. government starting this week.
 
 Currently, the pharmacies were dependent on states to obtain the pills. 
		The government sends the treatments to select pharmacies, as well as 
		directly to states and community centers. Under the current system, the 
		treatments are available in around 20,000 locations.
 
 "There's more room to save more lives by getting this medication to more 
		people," a senior administration official told reporters on a press 
		call.
 
 The administration expects to increase their direct distribution to over 
		30,000 locations soon and reach 40,000 sites over the coming weeks, the 
		official said.
 
 Demand for Paxlovid has been unexpectedly light due to complicated 
		eligibility requirements, reduced testing, and potential for drug 
		interactions.
 
		
		 
		Paxlovid was expected to be a major tool in the fight against COVID 
		after it reduced hospitalizations or deaths in high-risk patients by 
		around 90% in a clinical trial. 
		There are only a few proven antiviral treatments. The others are Merck & 
		Co's far less effective rival pill molnupiravir, and Gilead Sciences 
		Inc's intravenous remdesivir.
 [to top of second column]
 | 
            
			 
            
			Pfizer's coronavirus disease (COVID-19) pill Paxlovid is packaged in 
			Ascoli, Italy, in this undated image obtained by Reuters on November 
			16, 2021. Pfizer/Handout via REUTERS 
            
			 The United States has agreed to buy 
			up to 20 million pills at around $530 a course and Pfizer is on pace 
			to produce 3.5 million courses earmarked for U.S. use by the end of 
			April. 
 Through the first half of April, U.S. data shows it has distributed 
			around 1.5 million courses and that pharmacies still have over 
			500,000 available.
 
 The government also plans to roll out more federally supported test 
			sites as part of its "Test to Treat" initiative that allows 
			Americans to get tested for COVID-19 at a pharmacy and receive free 
			pills if they test positive.
 
 There are currently 2,200 such sites and the White House expects an 
			additional 10,000 to come online right away.
 
 The administration also aims to boost patient and provider awareness 
			through public education campaigns.
 
 (Reporting by Ahmed Aboulenein; Editing by Caroline Humer and Sandra 
			Maler)
 
			[© 2022 Thomson Reuters. All rights 
			reserved.]  This 
			material may not be published, broadcast, rewritten or 
			redistributed.  
			Thompson Reuters is solely responsible for this content. 
			
			 |